Univercells is a global producer of innovative biomanufacturing solutions for cell and gene therapy research, development, and commercial manufacturing.

Univercells Technologies is headquartered in Nivelles, Belgium, and employs over 100 people worldwide. It made around €10 million in revenue in 2022.

Univercells is being acquired from Gamma Biosciences and Univercells SA and will be a part of the Donaldson Life Sciences segment. 

"The acquisition of Univercells Technologies represents an important next step in Donaldson's life sciences strategy, as we continue to expand our product portfolio aimed at providing customers with a comprehensive, differentiated offering," commented Tod Carpenter, chairman, president, and chief executive officer of Donaldson. 

"Univercells Technologies' engineered systems provide close adjacencies with our previous life sciences acquisitions as well as with our growing organic product suite," he added.

Price Action: DCI shares closed higher by 0.83% at $62.31 on Thursday.

Photo Via Company